X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Lauren Neves

Lauren Neves Lauren Neves is a Director of Policy at PhRMA focusing on the value of cancer medicines, medication adherence, and payment and delivery reform. Prior to joining PhRMA, Lauren earned her law degree and worked as a market access and health policy consultant to health care and pharmaceutical clients.

Recent Posts

PhRMA submits comments urging CMS to withdraw coverage proposal

By Lauren Neves  |    February 11, 2022
In comments submitted this week, PhRMA urged the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the...   Read More

5 Ways to improve ICER’s value assessment framework

By Lauren Neves  |    June 20, 2019
The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...   Read More

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

By Lauren Neves  |    September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...   Read More

How ICER’s assessment of a new class of migraine treatments fails patients

By Lauren Neves  |    July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...   Read More

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

By Lauren Neves  |    May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a new...   Read More

RA medicines often demonstrate far greater benefits to patients than initially understood

By Lauren Neves  |    April 5, 2017
In the last decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients’ treatment options and significantly improved outcomes,...   Read More

How do multiple sclerosis patients define value?

By Lauren Neves  |    February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...   Read More

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

By Lauren Neves  |    October 20, 2016
The value of recent advances in non-small cell lung cancer (NSCLC) is undeniable. NSCLC is a devastating illness – 17.7 percent of lung cancer patients survive only five years following their...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the authors...   Read More

4 recommendations for ICER

By Lauren Neves  |    September 26, 2016
For years, PhRMA has supported policies that ensure health care decisions are grounded in the best available evidence. In our policy solutions for delivering innovative treatments to patients...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."